A phase I/II safety and immunogenicity study of a combination of whole-killed HIV-1 antigen and Amplivax (TM) [IR 103], administered with or without IFA [incomplete Freund's adjuvant], in HIV-1 infected subjects on stable HAART

Trial Profile

A phase I/II safety and immunogenicity study of a combination of whole-killed HIV-1 antigen and Amplivax (TM) [IR 103], administered with or without IFA [incomplete Freund's adjuvant], in HIV-1 infected subjects on stable HAART

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2013

At a glance

  • Drugs IR 103 (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Sponsors Orchestra Therapeutics
  • Most Recent Events

    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top